Business
Genmab Portfolio Prioritization Update
COPENHAGEN, Denmark, December 29, 2025--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/395e6a8cd57d619f7f0edcb14030dae3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Dwt8sHNCxadogA3VuF1F5w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/395e6a8cd57d619f7f0edcb14030dae3","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bQlABTSuSGO8tHzu.JiJ_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/395e6a8cd57d619f7f0edcb14030dae3","width":1200,"height":350}},"lazy":false},{"type":"text","content":"Company Announcement","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Genmab to discontinue clinical development of acasunlimab following a portfolio review","length":86,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscape","length":138,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This decision does not impact Genmab’s full‑year 2025 financial guidance","length":72,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":296,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, December 29, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY® (epcoritamab), petosemtamab and rinatabart sesutecan (Rina‑S®), which are advancing in late‑stage development. This decision is consistent with Genmab’s disciplined portfolio prioritization and capital allocation framework.","length":761,"tagName":"p"},{"type":"text","content":""After careful consideration, we have decided to discontinue the acasunlimab program. Although the data have ...